Chagas Disease: Epidemiology, Diagnosis, Treatment and Global Challenges

Skryabina A. A.
Assistant, Chair for Infectious Diseases and Epidemiology, Faculty of Medicine¹

Fedoseev A. I.
Student, Chair for Infectious Diseases and Epidemiology, Faculty of Medicine¹

Fedoseeva M. I.
Student, Chair for Infectious Diseases and Epidemiology, Faculty of Medicine¹

1 - Pirogov Russian National Research Medical University, Moscow, Russian Federation

Skryabina Anna Aleksandrovna; e-mail: anna.skryabina.85@mail.ru

The study had no sponsorship.

None declared.

Chagas disease, caused by Trypanosoma cruzi, remains one of the most important tropical diseases despite more than a century of study. The disease affects about 6-8 million people worldwide, including regions where it was not previously endemic due to globalization and migration. Transmission of the pathogen is through vectors (triatom bugs), blood transfusions, organ transplants, and vertically from mother to child. Chagas disease includes two phases: acute, often asymptomatic, and chronic, which may be accompanied by severe cardiologic and gastroenterologic complications. Chronic cardiomyopathy, as one of the most severe manifestations, significantly impairs the quality of life of patients and requires significant resources for treatment, including heart transplantation. Diagnosis of the disease ranges from parasitologic methods in the acute phase to serologic tests in the chronic phase. Current treatment approaches include the use of benznidazole and nifurtimox, which are effective in the early stages but are limited due to side effects. Prospects for therapy include the use of gene therapy, vaccines and combined methods (vaccination and chemotherapy). Prevention of transmission, especially through donated blood and organs, remains important, it has already been successfully implemented in a number of countries. The epidemiologic features, clinical manifestations, modern methods of diagnostics and treatment of Chagas disease, as well as promising directions of its study are considered in the article. Special attention is paid to the global spread of the disease and control measures in non-endemic regions.

Chagas disease, Trypanosoma cruzi, epidemiology, parasitology, trypanosome, tropical diseases

10.29234/2308-9113-2025-13-2-38-55

1. Schofield C.J., Jannin J., Salvatella R. The future of Chagas disease control. Trends Parasitol. 2006; 22(12): 583-588, doi: 10.1016/j.pt.2006.09.011

2. Lidani K.C.F, Andrade F.A., Bavia L., Damasceno F.S., Beltrame M.H., Messias-Reason I.J., Sandri T.L. Chagas Disease: From Discovery to a Worldwide Health Problem. Front Public Health. 201; 7: 166, doi: 10.3389/fpubh.2019.00166

3. Prata A. Clinical and epidemiological aspects of Chagas disease. Lancet Infect Dis. 2001 Sep;1(2):92-100, doi: 10.1016/S1473-3099(01)00065-2

4. Медведева Е.А. Medvedeva E.A. Tropicheskie bolezni, vyzyvajushhie porazhenie miokarda. [Tropical diseases causing myocardial lesions.]. Kardiologija: novosti, mnenija, obuchenie [Cardiology: news, opinions, training] 2017; 3(14): 22-32. (In Russ.)

5. Bonney K.M. Chagas disease in the 21st century: a public health success or an emerging threat? Parasite 2014; 21: 11, doi: 10.1051/parasite/2014012

6. Lee B.Y., Bacon K.M., Bottazzi M.E., Hotez P.J. Global economic burden of Chagas disease: a computational simulation model. Lancet Infect Dis. 2013; 13(4): 342-348, doi: 10.1016/S1473-3099(13)70002-1

7. Abuhab A., Trindade E., Aulicino G.B., Fujii S., Bocchi E.A., Bacal F. Chagas’ cardiomyopathy: the economic burden of an expensive and neglected disease. Int J Cardiol. 2013; 168(3): 2375-2380, doi: 10.1016/j.ijcard.2013.01.262

8. Chagas C. Nova tripanozomiaze humana: estudos sobre a morfolojia e o ciclo evolutivo do Schizotrypanum cruzi n. gen., n. sp., ajente etiolojico de nova entidade morbida do homem. Memórias do Instituto Oswaldo Cruz 1909; 1(2): 159-218, doi: 10.1590/S0074-02761909000200008

9. Coutinho M., Freire O. Jr., Dias J.C. The noble enigma: Chagas’ nominations for the Nobel prize. Mem Inst Oswaldo Cruz 1999;.94 Suppl 1: 123-129, doi: 10.1590/s0074-02761999000700012

10. Bestetti R.B. The Non-Award of the Nobel Prize of 1921 to Carlos Chagas: A Tragic Mistake. Journal of Infectious Diseases & Therapy 2015; (3): 220, doi: 10.4172/2332-0877.1000220

11. Bestetti R.B., Couto L.B., Cardinalli-Neto A. When a misperception favors a tragedy: Carlos Chagas and the Nobel Prize of 1921. Int J Cardiol. 2013; 169(5): 327-330, doi: 10.1016/j.ijcard.2013.08.137

12. Chao C., Leone J.L., Vigliano C.A. Chagas disease: Historic perspective. Biochim Biophys Acta Mol Basis Dis. 2020; 1866(5): 165689, doi: 10.1016/j.bbadis.2020.165689

13. Araújo A., Jansen A.M., Reinhard K., Ferreira L.F. Paleoparasitology of Chagas disease – a review. Mem Inst Oswaldo Cruz 2009; 104 Suppl 1: 9-16, doi: 10.1590/s0074-02762009000900004

14. Lieke T., Steeg C., Graefe S.E., Fleischer B., Jacobs T. Interaction of natural killer cells with Trypanosoma cruzi-infected fibroblasts. Clin Exp Immunol. 2006; 145(2): 357-364, doi: 10.1111/j.1365-2249.2006.03118.x

15. Rassi A., Marin-Neto J.A. Chagas disease. Lancet 2010; 375(9723): 1388-1402, doi: 10.1016/S0140-6736(10)60061-X

16. Coura J.R. Chagas disease: control, elimination and eradication. Is it possible? Mem Inst Oswaldo Cruz 2013; 108(8): 962-967, doi: 10.1590/0074-0276130565

17. Stegenga M.E., van der Crabben S.N., Dessing M.C., Pater J.M., van den Pangaart P.S., et al. Effect of acute hyperglycaemia and/or hyperinsulinaemia on proinflammatory gene expression, cytokine production and neutrophil function in humans. Diabet Med. 2008; 25: 157-164, doi: 10.1111/j.1464-5491.2007.02348.x

18. Briceño-León R., Méndez Galván J. The social determinants of Chagas disease and the transformations of Latin America. Mem Inst Oswaldo Cruz 2007; 102 Suppl 1: 109-112, doi: 10.1590/s0074-02762007005000095

19. Pérez-Molina J.A., Molina I. Chagas disease. Lancet 2018; 391(10115): 82-94, doi: 10.1016/S0140-6736(17)31612-4

20. Coura J.R., Viñas P.A., Junqueira A.C.V. Ecoepidemiology, Short history and control of chagas disease in the endemic countries and the new challenge for non-endemic countries. Mem Inst Oswaldo Cruz 2014; 109(7): 856-862, doi: 10.1590/0074-0276140236

21. Kun H., Moore A., Mascola L., Steurer F., Lawrence G., Kubak B., Radhakrishna S., Leiby D., Herron R., Mone T., Hunter R., Kuehnert M. Chagas Disease in Transplant Recipients Investigation Team. Transmission of Trypanosoma cruzi by heart transplantation. Clin Infect Dis. 2009; 48(11) :1534-1540, doi: 10.1086/598931

22. Howard E.J., Xiong X., Carlier Y., Sosa-Estani S., Buekens P. Frequency of the congenital transmission of Trypanosoma cruzi: a systematic review and meta-analysis. BJOG. 2014; 121(1): 22-33, doi: 10.1111/1471-0528.12396

23. Useche Y., Pérez A.R., de Meis J., Bonomo A., Savino W. Central nervous system commitment in Chagas disease. Front Immunol. 2022; 13: 975106, doi: 10.3389/fimmu.2022.975106

24. Echeverría L.E., Rojas L.Z., Gómez-Ochoa S.A. Coagulation disorders in Chagas disease: A pathophysiological systematic review and meta-analysis. Thromb Res. 2021; 201: 73-83, doi: 10.1016/j.thromres.2021.02.025

25. Echavarría N.G., Echeverría L.E., Stewart M., Gallego C., Saldarriaga C. Chagas Disease: Chronic Chagas Cardiomyopathy. Curr Probl Cardiol. 2021; 46(3): 100507, doi: 10.1016/j.cpcardiol.2019.100507

26. Shelton W.J., Gonzalez J.M. Outcomes of patients in Chagas disease of the central nervous system: a systematic review. Parasitology 2024; 151(1): 15-23, doi: 10.1017/S0031182023001117

27. Rassi A. Jr., Marin J.A. Neto, Rassi A. Chronic Chagas cardiomyopathy: a review of the main pathogenic mechanisms and the efficacy of aetiological treatment following the BENznidazole Evaluation for Interrupting Trypanosomiasis (BENEFIT) trial. Mem Inst Oswaldo Cruz 2017; 112(3): 224-235, doi: 10.1590/0074-02760160334

28. Torrico F., Gascón J., Barreira F., Blum B., Almeida I.C., Alonso-Vega C., Barboza T., Bilbe G., Correia E., Garcia W., Ortiz L., Parrado R., Ramirez J.C., Ribeiro .I, Strub-Wourgaft N., Vaillant M., Sosa-Estani S. BENDITA study group. New regimens of benznidazole monotherapy and in combination with fosravuconazole for treatment of Chagas disease (BENDITA): a phase 2, double-blind, randomised trial. Lancet Infect Dis. 2021; 21(8): 1129-1140, doi: 10.1016/S1473-3099(20)30844-6

29. Ribeiro A.L., Nunes M.P., Teixeira M.M., Rocha M.O.C. Diagnosis and management of Chagas disease and cardiomyopathy. Nat Rev Cardiol. 2012; 9(10): 576-589, doi: 10.1038/nrcardio.2012.109

30. Matsuda N.M., Miller S.M., Evora P.R.B. The chronic gastrointestinal manifestations of Chagas disease. Clinics (Sao Paulo) 2009; 64(12): 1219-1224, doi: 10.1590/S1807-59322009001200013

31. Brutus L., Castillo H., Bernal C., Salas N.A., Schneider D., Santalla J.A., Chippaux J.P. Detectable Trypanosoma cruzi parasitemia during pregnancy and delivery as a risk factor for congenital Chagas disease. Am J Trop Med Hyg. 2010; 83(5): 1044-1047, doi: 10.4269/ajtmh.2010.10-0326

32. Hamilton P.B., Teixeira M.M., Stevens J.R. The evolution of Trypanosoma cruzi: the ‘bat seeding’ hypothesis. Trends Parasitol. 2012; 28(4): 136-141, doi: 10.1016/j.pt.2012.01.006

33. Miles M.A. The discovery of Chagas disease: progress and prejudice. Infect Dis Clin North Am. 2004; 18(2): 247-260, table of contents, doi: 10.1016/j.idc.2004.01.005

34. Nóbrega A.A., Garcia M.H., Tatto E., Obara M.T., Costa E., Sobel J., Araujo W.N. Oral transmission of Chagas disease by consumption of acai palm fruit, Brazil. Emerg Infect Dis. 2009; 15(4): 653-635, doi: 10.3201/eid1504.081450

35. Pinazo M.J., Gascon J. The importance of the multidisciplinary approach to deal with the new epidemiological scenario of Chagas disease (global health). Acta Trop. 2015; 151: 16-20, doi: 10.1016/j.actatropica.2015.06.013

36. Conners E.E., Vinetz J.M., Weeks J.R., Brouwer K.C. A global systematic review of Chagas disease prevalence among migrants. Acta Trop. 2016; 156: 68-78, doi: 10.1016/j.actatropica.2016.01.002

37. Antinori S., Galimberti L., Bianco R., Grande R., Galli M., Corbellino M. Chagas disease in Europe: a review for the internist in the globalized world. Eur J Intern Med. 2017: 43: 6-15, doi: 10.1016/j.ejim.2017.05.001

38. Bern C., Montgomery S.P., Katz L., Caglioti S., Stramer S.L. Chagas disease and the US blood supply. Curr Opin Infect Dis. 2008; 21(5): 476-482, doi: 10.1097/QCO.0b013e32830ef5b6

39. Manne-Goehler J., Umeh C.A., Montgomery S.P., Wirtz V.J. Estimating the burden of Chagas disease in the United States. PLoS Negl Trop Dis. 2016; 10(11): e0005033, doi: 10.1371/journal.pntd.0005033

40. Schwartz B.S., Paster M., Ison M.G., Chin-Hong P.V. Organ donor screening practices for trypanosoma cruzi infection among US organ procurement organizations. Am J Transplant. 2011; 11(4): 848-851, doi: 10.1111/j.1600-6143.2011.03436.x

41. Rodriguez-Guardado A., González M.L., Rodriguez M., Flores-Chavez M., Boga J.A., Gascon J. Trypanosoma cruzi infection in a Spanish liver transplant recipient. Clin Microbiol Infect. 2015; 21(7): 687.e1-3, doi: 10.1016/j.cmi.2015.03.022

42. Requena-Mendez A., Albajar-Viñas P., Angheben A., Chiodini P., Gascón J., Muñoz J. Health policies to control Chagas disease transmission in European countries. PLoS Negl Trop Dis. 2014; 8(10): e3245, doi: 10.1371/journal.pntd.0003245

43. Liu Q., Zhou X.-N. Preventing the transmission of American trypanosomiasis and its spread into non-endemic countries. Infect Dis Poverty. 2015:4:60, doi: 10.1186/s40249-015-0092-7

44. Alpern J.D., Lopez-Velez R., Stauffer W.M. Access to benznidazole for Chagas disease in the United States – Cautious optimism? PLoS Negl Trop Dis. 2017; 11(9): e0005794, doi: 10.1371/journal.pntd.0005794

45. Nonaka C.K.V., Sampaio G.L., Silva K.N., Khouri R., Macedo C.T., Chagas Translational Research Consortium, Rogatto S.R., Ribeiro Dos Santos R., Souza B.S.F., Soares M.B.P. Therapeutic miR-21 Silencing Reduces Cardiac Fibrosis and Modulates Inflammatory Response in Chronic Chagas Disease. Int J Mol Sci. 2021; 22(7): 3307, doi: 10.3390/ijms22073307

46. Santos E.S., Silva D.K.C., Dos Reis B.P.Z.C., Barreto B.C., Cardoso C.M.A., Ribeiro Dos Santos R., Meira C.S., Soares M.B.P. Immunomodulation for the Treatment of Chronic Chagas Disease Cardiomyopathy: A New Approach to an Old Enemy. Front Cell Infect Microbiol. 2021; 11: 765879, doi: 10.3389/fcimb.2021.765879

47. Jones K.M., Mangin E.N., Reynolds C.L., Villanueva L.E., Cruz J.V., Versteeg L., Keegan B., Kendricks A., Pollet J., Gusovsky F., Bottazzi M.E., Hotez P.J. Vaccine-linked chemotherapy improves cardiac structure and function in a mouse model of chronic Chagas disease. Front Cell Infect Microbiol. 2023; 13: 1106315, doi: 10.3389/fcimb.2023.1106315

48. Zaidel E.J., Forsyth C.J., Novick G., Marcus R., Ribeiro A.L.P., Pinazo M.J., Morillo C.A., Echeverría L.E., Shikanai-Yasuda M.A., Buekens P., Perel P., Meymandi S.K., Ralston K., Pinto F., Sosa-Estani S. COVID-19: Implications for People with Chagas Disease. Glob Heart. 2020; 15(1): 69, doi: 10.5334/gh.891